C

CARsgen Therapeutics

Sustainability Report and Carbon Intensity Rankings

Is CARsgen Therapeutics doing their part?

Their DitchCarbon score is 35

CARsgen Therapeutics has a DitchCarbon Score of 35 out of 100, indicating a moderate level of sustainability in their operations. This score suggests that the company’s carbon intensity is relatively high, implying there is significant room for improvement in reducing emissions. Efforts to enhance sustainability practices could lead to a lower carbon intensity and a higher DitchCarbon Score.

This was calculated based on 30+ company specific emissions data points, the higher the score, the better. Check out our methodology.

Industry emissions intensity

Very low

Low

Medium

High

Very high

CARsgen Therapeutics is part of the health and social services industry, which has a low carbon intensity ranking compared to other industries. Some industries are more damaging than others, this ranking gives you an indication of how carbon intensive the industry is which this company operates in.

Location emissions intensity

Very low

Low

Unknown

High

Very high

CARsgen Therapeutics, located in China, operates in a region with a carbon intensity rating that influences its environmental impact. The sustainability efforts of the company are affected by China’s national strategies and policies on carbon emissions.

Unlock 30+ emissions intelligence data points

Get the emissions intelligence you need, no surveys required.

– Historical Scope 1, 2 and 3 emissions

– Coverage of all industries, product level data

– Emissions forecasting, assurances

Unlock 30+ emissions data points on CARsgen Therapeutics

Get the emissions intelligence you need, no surveys required.

– Historical Scope 1, 2 and 3 emissions

– Coverage of all industries, product level data

– Emissions forecasting, assurances

6.56%

...this company is doing 6.56% worse in emissions than the industry average.

Founded in 2014 and headquartered in Shanghai’s JUKE Biopark, CARsgen Therapeutics operates in the health and social services industry, specializing in CAR-T therapies for solid tumors. The company has pioneered CAR-T clinical trials for conditions such as hepatocellular carcinoma and glioblastoma, and holds a broad portfolio of proprietary technologies and patents. CARsgen is dedicated to advancing global clinical progress and providing innovative, safe, and effective treatments for cancer patients.

Compare CARsgen Therapeutics with other companies in the same industry –>

emission intelligence's platform recommendations for CARsgen Therapeutics

CARsgen Therapeutics could reduce its emissions by transitioning to renewable energy sources for all purchased electricity, heat, steam, and cooling, which has the potential to lower their emissions by 30%.

Bad news, CARsgen Therapeutics hasn't committed to SBTi goals yet

CARsgen Therapeutics has not yet established specific commitments with the Science Based Targets initiative (SBTi). This means the company is either in the process of defining its climate action goals or has not yet taken the step to align its emissions reduction targets with scientific consensus.

Not participating

Claim this profile

Are you associate with this company?
Help us improve our data and claim this profile.

Our methodology

Read about our emission calculation methodologies, and what the DitchCarbon Score means.

Other company reports in this industry

Looking for a specific company?

Search our company directory or contact us for custom data requests.

C

CARsgen Therapeutics

Sustainability Report and Carbon Intensity Rankings

Is CARsgen Therapeutics doing their part?

Their DitchCarbon score is 35

Industry emissions intensity

Very low

Low

Medium

High

Very high

Location emissions intensity

Very low

Low

Unknown

High

Very high

Unlock 30+ emissions intelligence data points

Unlock 30+ emissions data points on CARsgen Therapeutics

...this company is doing 6.56% worse in emissions than the industry average.

emission intelligence's platform recommendations for CARsgen Therapeutics

Bad news, CARsgen Therapeutics hasn't committed to SBTi goals yet

Claim this profile

Our methodology

Other company reports in this industry

Looking for a specific company?

Quicklinks

Resources

Get in touch